This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in
relapse/refractory Acute Myeloid Leukemia (AML).
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of
QN-030a in patients with r/r AML, where a "3+3" enrollment schema will be utilized at dose
escalation stage. Up to 18 patients will be enrolled.